StoxAnthem Biosciences vs Glaxosmithkline Pharmaceuticals: share price & financials comparison
NSE: ANTHEM vs GLAXO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Anthem Biosciences vs Glaxosmithkline Pharmaceuticals at a glance
Anthem Biosciences (ANTHEM) has a market capitalisation of ₹52,800 Cr, against ₹45,277 Cr for Glaxosmithkline Pharmaceuticals (GLAXO). Over the past year Anthem Biosciences has returned +33.4%, compared with +0.5% for Glaxosmithkline Pharmaceuticals. On valuation, Glaxosmithkline Pharmaceuticals trades at a lower P/E of 87.9 versus 278.2. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 5.8%). Anthem Biosciences comes out ahead on momentum and technicals. Glaxosmithkline Pharmaceuticals comes out ahead on size, profitability and growth. Across the scored metrics below, Anthem Biosciences leads on 6 and Glaxosmithkline Pharmaceuticals on 5. On StoxGud's 10-point checklist, Anthem Biosciences scores 6/10 and Glaxosmithkline Pharmaceuticals scores 7/10.
| Metric | Anthem Biosciences | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹52,800 Cr | ₹45,277 Cr |
| Revenue (latest FY) | ₹2,124 Cr | ₹3,822 Cr |
| Net profit (latest FY) | ₹592 Cr | ₹1,036 Cr |
| Valuation | ||
| P/E | 278.2 | 87.9 |
| P/B | 16.09 | 24.07 |
| Dividend yield | — | 1.58% |
| Profitability | ||
| Return on equity | 5.8% | 27.4% |
| Net profit margin | 9.3% | 12.4% |
| Operating margin | 41.4% | 34.1% |
| Growth | ||
| Revenue growth (YoY) | +8.0% | +20.8% |
| Revenue CAGR (multi-year) | — | +2.9% |
| Financial health | ||
| Debt to equity | 0.01 | 0.00 |
| Momentum | ||
| 1-month return | +7.7% | +5.4% |
| 1-year return | +33.4% | +0.5% |
| 3-year CAGR | — | +22.0% |
| 5-year CAGR | — | +10.1% |
| 10-year CAGR | — | +7.2% |
| Distance from 52W high | -2.2% | -14.0% |
| Technicals | ||
| RSI (14) | 84 | 72 |
| Price vs 200-day avg | +20.2% | +5.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Anthem Biosciences | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Anthem Biosciences or Glaxosmithkline Pharmaceuticals?
Anthem Biosciences has a market cap of ₹52,800 Cr and Glaxosmithkline Pharmaceuticals has a market cap of ₹45,277 Cr as of 13 Nov 2026.
Which has a lower P/E, Anthem Biosciences or Glaxosmithkline Pharmaceuticals?
Glaxosmithkline Pharmaceuticals has the lower P/E: Anthem Biosciences trades at 278.2 and Glaxosmithkline Pharmaceuticals at 87.9.
Which gave better returns in the last year, Anthem Biosciences or Glaxosmithkline Pharmaceuticals?
Anthem Biosciences did better: Anthem Biosciences returned +33.4% and Glaxosmithkline Pharmaceuticals returned +0.5% over one year.
What is the difference between Anthem Biosciences and Glaxosmithkline Pharmaceuticals?
Both are NSE-listed companies in Healthcare. Anthem Biosciences is about 1.2 times the size of Glaxosmithkline Pharmaceuticals by market cap. In the latest financial year Anthem Biosciences reported revenue of ₹2,124 Cr and Glaxosmithkline Pharmaceuticals ₹3,822 Cr. Operating margin is 41.4% for Anthem Biosciences and 34.1% for Glaxosmithkline Pharmaceuticals. Debt to equity is 0.01 for Anthem Biosciences and 0.00 for Glaxosmithkline Pharmaceuticals.
Which is better, Anthem Biosciences or Glaxosmithkline Pharmaceuticals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Anthem Biosciences leads on 6 and Glaxosmithkline Pharmaceuticals on 5. Anthem Biosciences is ahead on momentum and technicals. Glaxosmithkline Pharmaceuticals is ahead on size, profitability and growth. On StoxGud's rules-based checklist Anthem Biosciences scores 6/10 and Glaxosmithkline Pharmaceuticals scores 7/10. This is information, not advice: consult a SEBI-registered adviser before investing.